Biotica wins landmark European Patent Appeal Cambridge, UK, July 18, 2007 – Biotica Technology Ltd., a private UK biotechnology company, today announced that its appeal (T1181/06) against the modular polyketide synthase engineering patent exclusively licensed to Kosan Biosciences, EP 0 725 778, had been successful, and the European Patent Office (EPO) Board of Appeal had revoked the patent in its entirety. “This final decision by the EPO clears the way for our polyketide engineering technology in Europe, for which we have our own strong IP portfolio, and will allow us to further broaden its scope,” said Professor Peter Leadlay, co-founder and Director of Biotica Technology Ltd. The patent, EP 0 725 778 (application no. EP94928169.5), titled “Recombinant Production of Novel Polyketides”, had originally been filed by the Leland Stanford Junior University and John Innes Centre.
